Studies using transcriptome analysis, confirmed by metabolome analysis, revealed that enarodustat, one of novel therapeutic agents against anemia in chronic kidney disease from the class of HIF stabilizers (HIF-prolyl hydroxylase inhibitors), that acts by increasing endogenous erythropoietin production, could serve to counteract the alterations in incipient diabetic renal metabolism and relieve oxidative stress in renal tissue [94]. Here, EPO is linked to anemia.